1
|
Riccardi E, Guida G, Pizzimenti S, Ricciardolo FLM. The "serial switcher" in severe asthma. Pulmonology 2024; 30:90-92. [PMID: 36717295 DOI: 10.1016/j.pulmoe.2022.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 12/02/2022] [Accepted: 12/05/2022] [Indexed: 01/30/2023] Open
Affiliation(s)
- E Riccardi
- Department of Clinical and Biological Sciences, University of Turin, Italy
| | - G Guida
- Department of Clinical and Biological Sciences, University of Turin, Italy; Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy
| | - S Pizzimenti
- Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy
| | - F L M Ricciardolo
- Department of Clinical and Biological Sciences, University of Turin, Italy; Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy; Institute of Translational Pharmacology, National Research Council (IFT-CNR), section of Palermo, Italy.
| |
Collapse
|
2
|
Riberi L, Falco A, Mossetto C, Riccardi E, Sciolla M, Pizzimenti S, Perboni A, Grande A, Demichelis S, Messore B. P058 Resolution of chronic pneumothorax in an adult patient with severe cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00391-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Bessone F, Argenziano M, Grillo G, Ferrara B, Pizzimenti S, Barrera G, Cravotto G, Guiot C, Stura I, Cavalli R, Dianzani C. Low-dose curcuminoid-loaded in dextran nanobubbles can prevent metastatic spreading in prostate cancer cells. Nanotechnology 2019; 30:214004. [PMID: 30654342 DOI: 10.1088/1361-6528/aaff96] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Preventing recurrences and metastasis of prostate cancer after prostatectomy by administering adjuvant therapies is quite a controversial issue. In addition to effectiveness, absence of side effects and long term toxicity are mandatory. Curcuminoids (Curc) extracted with innovative techniques and effectively loaded by polymeric nanobubbles (Curc-NBs) satisfy such requirements. Curc-NBs showed stable over 30 d, were effectively internalized by tumor cells and were able to slowly release Curc in a sustained way. Significant biological effects were detected in PC-3 and DU-145 cell lines where Curc-NBs were able to inhibit adhesion and migration, to promote cell apoptosis and to affect cell viability and colony-forming capacity in a dose-dependent manner. Since the favourable effects are already detectable at very low doses, which can be reached at a clinical level, the actual drug concentration can be visualized and monitored by US or MRI, Curc-NBs can be proposed as an effective adjuvant theranostic tool.
Collapse
Affiliation(s)
- F Bessone
- Department of Drug Science & Technology, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Heffler E, Landi M, Caruso C, Fichera S, Gani F, Guida G, Liuzzo MT, Pistorio MP, Pizzimenti S, Riccio AM, Seccia V, Ferrando M, Malvezzi L, Passalacqua G, Gelardi M. Nasal cytology: Methodology with application to clinical practice and research. Clin Exp Allergy 2018; 48:1092-1106. [PMID: 29904978 DOI: 10.1111/cea.13207] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Nasal cytology is an easy, cheap, non-invasive and point-of-care method to assess nasal inflammation and disease-specific cellular features. By means of nasal cytology, it is possible to distinguish between different inflammatory patterns that are typically associated with specific diseases (ie, allergic and non-allergic rhinitis). Its use is particularly relevant when other clinical information, such as signs, symptoms, time-course and allergic sensitizations, is not enough to recognize which of the different rhinitis phenotypes is involved; for example, it is only by means of nasal cytology that it is possible to distinguish, among the non-allergic rhinitis, those characterized by eosinophilic (NARES), mast cellular (NARMA), mixed eosinophilic-mast cellular (NARESMA) or neutrophilic (NARNE) inflammation. Despite its clinical usefulness, cheapness, non-invasiveness and easiness, nasal cytology is still underused and this is at least partially due to the fact that, as far as now, there is not a consensus or an official recommendation on its methodological issues. We here review the scientific literature about nasal cytology, giving recommendations on how to perform and interpret nasal cytology.
Collapse
Affiliation(s)
- E Heffler
- Department of Biomedical Sciences, Humanitas University, Milano, Italy.,Personalized Medicine, Asthma and Allergy Unit, Humanitas Clinical and Research Center, Humanitas University, Milano, Italy
| | - M Landi
- Institute of Biomedicine and Molecular Immunology, National Research Council of Italy, Palermo, Italy.,Paediatric National Healthcare System, Torino, Italy
| | - C Caruso
- Allergy Unit, Fondazione Policlinico Gemelli, Presidio Columbus, Rome, Italy
| | - S Fichera
- Respiratory Medicine and Allergy, University of Catania, Catania, Italy
| | - F Gani
- Respiratory Allergy, A.O.U. San Luigi, Orbassano, Torino, Italy
| | - G Guida
- Allergy and Lung Physiology, AO Santa Croce e Carle, Cuneo, Italy
| | - M T Liuzzo
- Respiratory Medicine and Allergy, University of Catania, Catania, Italy
| | - M P Pistorio
- Respiratory Medicine and Allergy, University of Catania, Catania, Italy
| | - S Pizzimenti
- Respiratory Medicine Unit, National Health System, ASL Città di Torino, Torino, Italy
| | - A M Riccio
- Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genova, Italy
| | - V Seccia
- 1st Otorhinolaryngology Unit, Department of Medical and Surgical Pathology, Pisa University Hospital, Pisa, Italy
| | - M Ferrando
- Department of Biomedical Sciences, Humanitas University, Milano, Italy.,Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genova, Italy
| | - L Malvezzi
- Department of Otolaryngology, Humanitas Clinical and Research Center, Milano, Italy
| | - G Passalacqua
- Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genova, Italy
| | - M Gelardi
- Section of Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari, Bari, Italy
| |
Collapse
|
5
|
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 2015; 35:1541-53. [PMID: 26119935 PMCID: PMC4695331 DOI: 10.1038/onc.2015.219] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Revised: 04/09/2015] [Accepted: 04/28/2015] [Indexed: 12/31/2022]
Abstract
Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an unmet need for new therapeutic approaches to target chemotherapy-resistant UCC. Yes-associated protein (YAP) is a transcriptional co-activator that has been associated with bladder cancer progression and cisplatin resistance in ovarian cancer. In contrast, YAP has been shown to induce DNA damage associated apoptosis in non-small cell lung carcinoma. However, no data have been reported on the YAP role in UCC chemo-resistance. Thus, we have investigated the potential dichotomous role of YAP in UCC response to chemotherapy utilizing two patient-derived xenograft models recently established. Constitutive expression and activation of YAP inversely correlated with in vitro and in vivo cisplatin sensitivity. YAP overexpression protected while YAP knock-down sensitized UCC cells to chemotherapy and radiation effects via increased accumulation of DNA damage and apoptosis. Furthermore, pharmacological YAP inhibition with verteporfin inhibited tumor cell proliferation and restored sensitivity to cisplatin. In addition, nuclear YAP expression was associated with poor outcome in UCC patients who received perioperative chemotherapy. In conclusion, these results suggest that YAP activation exerts a protective role and represents a pharmacological target to enhance the anti-tumor effects of DNA damaging modalities in the treatment of UCC.
Collapse
Affiliation(s)
- E Ciamporcero
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - H Shen
- Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - S Ramakrishnan
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Cancer Pathology & Prevention, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - S Yu Ku
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Cancer Pathology & Prevention, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - S Chintala
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - L Shen
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - R Adelaiye
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Cancer Pathology & Prevention, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - K M Miles
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - C Ullio
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - S Pizzimenti
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - M Daga
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - G Azabdaftari
- Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - K Attwood
- Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - C Johnson
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - J Zhang
- Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - G Barrera
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - R Pili
- Department of Medicine, Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.,Department of Medicine, Indiana University, Indianapolis, IN, USA
| |
Collapse
|
6
|
|
7
|
Badiu I, Olivieri E, Montagni M, Guida G, Mietta S, Pizzimenti S, Caminati M, Yacoub MR, Tombetti E, Preziosi D, Quecchia C, Minetti S, Facchetti S, Fassio F, Massaro I, Corradi L, Turi MC, Colagiovanni A, Pascolini L, Rossi FW, Losappio L, Sansone L, Imbesi S, Leto Barone S, Mistrello G, Heffler E. Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy. Int J Immunopathol Pharmacol 2014; 26:801-6. [PMID: 24067481 DOI: 10.1177/039463201302600328] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Buckwheat allergy is considered a rare food allergy outside of Asia. In Europe, buckwheat has been described mainly as a hidden allergen. Data on the prevalence of buckwheat hypersensitivity in non-Asian countries is very poor. The aim of this multicenter study was to evaluate the prevalence of buckwheat sensitization and its association with other sensitizations among patients referred to allergy clinics in different geographic areas of Italy. All patients referred to 18 Italian allergy clinics from February through April 2011 were included in the study and evaluated for sensitization to buckwheat and other allergens depending on their clinical history. A total of 1,954 patients were included in the study and 61.3 percent of them were atopic. Mean prevalence of buckwheat sensitization was 3.6 percent with significant difference between Northern (4.5 percent), Central (2.2 percent) and Southern (2.8 percent) regions. This is, to our knowledge, the largest epidemiological survey on buckwheat allergy reported outside of Asia. Buckwheat is an emerging allergen in Italy, being more frequently associated to sensitization in Northern regions.
Collapse
Affiliation(s)
- I Badiu
- Junior Member Group of Italian Society of Allergology and Clinical Immunology (SIAIC), Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Heffler E, Nebiolo F, Asero R, Guida G, Badiu I, Pizzimenti S, Marchese C, Amato S, Mistrello G, Canaletti F, Rolla G. Clinical manifestations, co-sensitizations, and immunoblotting profiles of buckwheat-allergic patients. Allergy 2011; 66:264-70. [PMID: 20804471 DOI: 10.1111/j.1398-9995.2010.02469.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Buckwheat allergy is a rare food allergy in Europe and North America, whereas it is often described and studied in Asia. The aim of this study was to describe a series of patients with proven buckwheat allergy evaluated in an Italian allergy clinic. Co-sensitization to other food and inhalant allergens and immunoblotting profiles of buckwheat-allergic patients were studied. METHODS Patients with suspected buckwheat allergy who attended the allergy clinic between January 1, 2006, and September 30, 2008, were evaluated. All patients underwent skin prick tests for a standard panel of inhalant and food allergens, prick-by-prick with buckwheat flour, buckwheat-specific IgE determinations, and double-blind placebo-controlled food challenge (DBPCFC) with buckwheat flour. Immunoblotting with buckwheat flour extract was performed on sera from buckwheat-allergic patients. RESULTS Among 72 patients with suspected buckwheat allergy, 30 (41.7%) were sensitized to buckwheat and 24 had a positive DBPCFC. The mean buckwheat IgE level was 6.23 kUA/l (range, 0.16 to >100 kUA/l). Several IgE-binding proteins were identified and grouped into three patterns: a 16-kDa band in patients with predominantly gastrointestinal symptoms with grass and wheat flour co-sensitization, a 25-kDa band in patients with predominantly cutaneous symptoms and a low frequency of co-sensitization, and a 40-kDa band in patients with anaphylaxis and a low frequency of co-sensitization. CONCLUSIONS Buckwheat allergy is an emerging food allergy in Italy. We identified three distinct patterns of clinical and laboratory characteristics, suggesting that specific allergens could be more frequently associated with clinical manifestations of different severity.
Collapse
Affiliation(s)
- E Heffler
- Allergy and Clinical Immunology, University of Torino, ASO Mauriziano Umberto I, Largo Turati 62, Turin, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
De Luigi A, Pizzimenti S, Quadri P, Lucca U, Tettamanti M, Fragiacomo C, De Simoni MG. Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis 2002; 11:308-14. [PMID: 12505423 DOI: 10.1006/nbdi.2002.0556] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Whether peripheral inflammatory molecules can be considered markers of dementia is still an open issue. We have investigated the presence of circulating cytokines and the ability of blood cells to release them in response to an inflammatory stimulus in patients with different types of dementia and in age-matched controls. A significant increase in circulating interleukin-1beta in moderate Alzheimer and in multiinfarct (145 and 224 times control concentration, respectively) dementia and in circulating tumor necrosis factor-alpha concentration in multiinfarct dementia patient group (156%) were found. Tumor necrosis factor-alpha and interleukin-6 released from blood cells after exposure to lipopolysaccharide were significantly reduced in moderate Alzheimer (60%, both cytokines) and multiinfarct patients (71 and 50%, respectively), while interleukin-10 was decreased only in multiinfarct patients (61%). The results show that patients with Alzheimer disease or multiinfarct dementia have an upregulation of circulating cytokines and a downregulation of cytokines released by blood cells.
Collapse
Affiliation(s)
- A De Luigi
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|
10
|
Rinaldi M, Barrera G, Spinsanti P, Pizzimenti S, Ciafrè SA, Parella P, Farace MG, Signori E, Dianzani MU, Fazio VM. Growth inhibition and differentiation induction in murine erythroleukemia cells by 4-hydroxynonenal. Free Radic Res 2001; 34:629-37. [PMID: 11697038 DOI: 10.1080/10715760100300521] [Citation(s) in RCA: 203] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
4-Hydroxynonenal (HNE) is one of the major end products of lipid peroxidation. Here we show that the exposure of murine erythroleukemia (MEL) cells to 1 microM HNE, for 10.5 h over 2 days, induces a differentiation comparable with that observed in cells exposed to DMSO for the whole experiment (7 days). The exposure of MEL cells for the same length of time demonstrates a higher degree of differentiation in HNE-treated than in DMSO-treated MEL cells. The protooncogene c-myc is down-modulated early, in HNE-induced MEL cells as well as in DMSO-treated cells. However, ornithine decarboxylase gene expression first increases and then decreases, during the lowering of the proliferation rate. These findings indicate that HNE, at a concentration physiologically found in many normal tissues and in the plasma, induces MEL cell differentiation by modulation of specific gene expression.
Collapse
Affiliation(s)
- M Rinaldi
- Laboratory of Molecular Medicine & Biotechnology, University Campus Bio-Medico, School of Medicine, Roma, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Barrera G, Pizzimenti S, Serra A, Fazio VM, Canuto RA, Dianzani MU. Effect of bioactive aldehydes on cell proliferation and c-myc expression in HL-60 human leukemic cells. Cancer Detect Prev 2001; 24:244-51. [PMID: 10975286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Lipid peroxidation produces several toxic carbonyls, including biologically active aldehydes. In previous studies, we demonstrated that 4-hydroxynonenal (HNE), one of the major products of lipoperoxidation, inhibited growth and c-myc expression in K562 and HL-60 human leukemic cells. In this study, we compared the HNE effects with those of 4-hydroxyoctenal (HOE), 4-hydroxyundecenal (HUE; different lengths of the lipophilic tail), and the analogous aldehydes 2-trans-nonanal (lacking the OH group) and nonenal (lacking the OH group and the trans CC double bond), on HL-60 cell proliferation and c-myc expression. HUE and HOE inhibited growth and c-myc expression in a dose-dependent fashion, with an effectiveness comparable with that of HNE, whereas 2-nonenal and nonanal did not affect these parameters. Our results showed that different aldehydes produced from lipid peroxidation may contribute to growth inhibition by c-myc downregulation and that the molecular features involved seem to be the hydroxy group and the trans CC double bond.
Collapse
Affiliation(s)
- G Barrera
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Italy
| | | | | | | | | | | |
Collapse
|
12
|
Rinaldi M, Barrera G, Aquino A, Spinsanti P, Pizzimenti S, Farace MG, Dianzani MU, Fazio VM. 4-Hydroxynonenal-induced MEL cell differentiation involves PKC activity translocation. Biochem Biophys Res Commun 2000; 272:75-80. [PMID: 10872805 DOI: 10.1006/bbrc.2000.2691] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
4-Hydroxynonenal (HNE) is a highly reactive aldehyde, produced by cellular lipid peroxidation, able to inhibit proliferation and to induce differentiation in MEL cells at concentrations similar to those detected in several normal tissues. Inducer-mediated differentiation of murine erythroleukemia (MEL) cells is a multiple step process characterized by modulation of several genes as well as by a transient increase in the amount of membrane-associated protein kinase C (PKC) activity. Here we demonstrate that a rapid translocation of PKC activity from cytosol to the membranes occurs during the differentiation induced by HNE. When PKC is completely translocated by phorbol-12-myristate-13-acetate (TPA), the degree of HNE-induced MEL cells differentiation is highly decreased. However, if TPA is washed out from the culture medium before the exposition to the aldehyde, HNE gradually resumes its differentiative ability. The incubation of cells with a selective inhibitor of PKC activity, bisindolylmaleimide GF 109203X, partially prevents the HNE-induced differentiation in MEL cells. In conclusion, our results demonstrate that HNE-induced MEL cell differentiation is preceded by a rapid translocation of PKC activity, and that the inhibition of this phenomenon prevents the onset of terminal differentiation.
Collapse
Affiliation(s)
- M Rinaldi
- Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico, School of Medicine, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Barrera G, Pizzimenti S, Muzio G, Maggiora M, Dianzani MU, Canuto RA. Enzymes metabolizing aldehydes in HL-60 human leukemic cells. Adv Exp Med Biol 1999; 463:517-22. [PMID: 10352727 DOI: 10.1007/978-1-4615-4735-8_65] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- G Barrera
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Ospedale S. Luigi Gonzaga, Orbassano, Italy
| | | | | | | | | | | |
Collapse
|
14
|
Pizzimenti S, Barrera G, Dianzani MU, Brüsselbach S. Inhibition of D1, D2, and A-cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal. Free Radic Biol Med 1999; 26:1578-86. [PMID: 10401624 DOI: 10.1016/s0891-5849(99)00022-2] [Citation(s) in RCA: 228] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
4-Hydroxynonenal (HNE), a product of lipid peroxidation, is an highly reactive aldehyde that, at concentration similar to those found in normal cells, blocks proliferation and induces a granulocytic-like differentiation in HL-60 cells. These effects are accompained by a marked increase in the proportion G0/G1 cells. The mechanisms of HNE action were investigated by analyzing the expression of the cyclins and cyclin-dependent protein kinases (CDKs), controlling the cell cycle progression. Data obtained by exposing cells to dimethyl sulfoxide (DMSO) were used for comparison. 4-Hydroxynonenal downregulated both mRNA and protein contents of cyclins D1, D2, and A until 24 h from the treatments, whereas DMSO inhibited cyclin D1 and D2 expression until the end of experiment (2 days) and induces an increase of cyclin A until 1 day. Cyclins B and E, and protein kinase CDK2 and CDK4 expressions were not affected by HNE, whereas DMSO induced an increase of cyclin E, B, and CDK2 from 8 h to 1 day. These data are in agreement with previous results indicating a different time-course of accumulation in G0/G1 phases of cells treated with HNE and DMSO and suggest that the HNE inhibitory effect on proliferation and cell cycle progression may depend by the downregulation of D1, D2, and A cyclin expression.
Collapse
Affiliation(s)
- S Pizzimenti
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Italy.
| | | | | | | |
Collapse
|
15
|
Barrera G, Pizzimenti S, Serra A, Ferretti C, Fazio VM, Saglio G, Dianzani MU. 4-hydroxynonenal specifically inhibits c-myb but does not affect c-fos expressions in HL-60 cells. Biochem Biophys Res Commun 1996; 227:589-93. [PMID: 8878557 DOI: 10.1006/bbrc.1996.1550] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
4-Hydroxynonenal, an aldehyde produced from lipid peroxidation of cellular membranes, inhibits growth and induces differentiation of HL-60 human leukemic cell line. Since it is highly unstable in the culture medium, its effectiveness is increased when added repeatedly to the cell suspension. We have previously demonstrated that HNE inhibits c-myc but not N-ras expression in HL-60 cells. Here we investigate its effect on the expression of c-myb and c-fos, two early genes involved in the induction of myeloid and monocytic differentiation. Moreover, since c-fos is directly correlated with the intracellular level of cAMP, we also analysed the cAMP concentration after aldehyde treatment. HNE significantly inhibits c-myb expression during and after repeated treatments. A single administration of 1 microM HNE decreases c-myb mRNA at 1 hour whereas 10 microM HNE inhibits c-myb expression from 3 to 6 hours after treatment, and then the expression returns to the control level. By contrast, c-fos expression and intracellular cAMP concentration do not show any significant change after HNE treatments.
Collapse
Affiliation(s)
- G Barrera
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Turin, Italy
| | | | | | | | | | | | | |
Collapse
|
16
|
Barrera G, Pizzimenti S, Muzio G, Maggiora M, Garramone A, Biasi F, Dianzani MU, Canuto RA. Enzymatic pattern of aldehyde metabolism during HL-60 cell differentiation. Biochem Biophys Res Commun 1996; 223:73-9. [PMID: 8660382 DOI: 10.1006/bbrc.1996.0848] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A number of metabolic changes, including modification of different enzyme activities, are linked to the acquisition of differentiated phenotype in HL-60 cells. Enzymes metabolizing aldehydes contribute to maintaining the intracellular steady-state concentration of aldehydes derived from lipid peroxidation. 4-Hydroxynonenal is one of the most important aldehydes produced by this process, and it is able to inhibit proliferation and induce differentiation of HL-60 human leukemic cells. We have now demonstrated that, after induction of HL-60 cell differentiation by 4-hydroxynonenal or DMSO, glutathione transferase activity increases in parallel to the degree of differentiation induction. Moreover, in 4-hydroxynonenal- or DMSO-treated cells, the concentration of reduced glutathione decreases five days after treatment. The rise of glutathione transferase activity, as well as the decrease of reduced glutathione, are possibly linked to the increase of detoxification capability of differentiated cells.
Collapse
Affiliation(s)
- G Barrera
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Barrera G, Pizzimenti S, Muraca R, Barbiero G, Bonelli G, Baccino FM, Fazio VM, Dianzani MU. Effect of 4-Hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Free Radic Biol Med 1996; 20:455-62. [PMID: 8720918 DOI: 10.1016/0891-5849(95)02049-7] [Citation(s) in RCA: 234] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
4-Hydroxynonenal (HNE) is a highly reactive aldehyde produced by lipid peroxidation of cellular membranes that inhibits growth and induces differentiation in HL-60 cells. Its mechanisms of action were investigated by analyzing the cell cycle distribution and the appearance of differentiated phenotypes in HL-60 cells. Data obtained by exposing cells to DMSO for 7.5 h (same time as for HNE treatment) or for the whole length of the experiments (5 d) were used for comparison. HNE induced a marked increase in the proportion of G0/G1 cells after 1 and 2 d. The brief DMSO treatment did not affect the distribution, whereas continuous exposure led to a progressive accumulation of cells in G0/G1 (maximal at day 5). The proportion of phagocytic cells gradually increased in HNE-treated and DMSO long-exposed cultures from day 2 and peaked at day 5 (35 and 63%, respectively), whereas the effect of the brief DMSO treatment was negligible. The expression of CD11b and CD67 increased in cells treated with HNE or continuously exposed to DMSO, whereas CD36 was expressed at low levels on both treatments. These results indicate that the pathway of the granulocytic differentiation induced by HNE in HL-60 cells differs from that of DMSO: with HNE, growth inhibition precedes the onset of differentiation, whereas in DMSO-treated cells the two processes are chronologically associated.
Collapse
Affiliation(s)
- G Barrera
- Dipartimento di Medicina ed Oncologia Sperimentale, Università di Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Barrera G, Muraca R, Pizzimenti S, Serra A, Rosso C, Saglio G, Farace MG, Fazio VM, Dianzani MU. Inhibition of c-myc expression induced by 4-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. Biochem Biophys Res Commun 1994; 203:553-61. [PMID: 8074703 DOI: 10.1006/bbrc.1994.2218] [Citation(s) in RCA: 234] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
4-Hydroxynonenal is a highly reactive aldehyde, produced by cellular lipid peroxidation, able to inhibit cell proliferation "in vitro" and "in vivo". Its concentration in non proliferating cells ranges up to 1 microM, whereas in the highly undifferentiated tumour cells, it is very low or undetectable. We have now demonstrated that micromolar concentrations of 4-hydroxynonenal inhibit c-myc but not N-ras expression in HL-60 human leukemic cells. This inhibitory effect is observed after an incubation of 1 hour with both 1 and 10 microM aldehyde. Moreover, we report that down-regulation of c-myc expression increases when repeated additions of 1 microM 4-hydroxynonenal are performed, to maintain the cells in presence of aldehyde for 7.5 hours. These results indicate that not only the concentration but also the length of exposure to the aldehyde is important in determining the extent of the c-myc expression inhibition and suggest a role of lipid peroxidation products in the control of gene expression.
Collapse
Affiliation(s)
- G Barrera
- Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|